Justice Alito Extends Administrative Stay of Mifepristone Order

Key Takeaways

• Alito extended the stay; deadline set for Thursday
• FDA has not filed a brief, signaling limited government concern
• Fifth Circuit order creates a split with Ninth Circuit on telemedicine mifepristone
• Supreme Court may grant certiorari or issue stays, shaping abortion drug regulation

Pulse Analysis

The Supreme Court’s latest administrative order, signed by Justice Samuel Alito, pushes the deadline for a pending stay on the Fifth Circuit’s injunction against telemedicine prescriptions of mifepristone to Thursday. The injunction, issued in early May, would have halted the federal allowance for patients to obtain the medication by video visit, effectively rolling back a 2023 FDA rule that expanded access. By extending the stay, the Court keeps the status quo while it deliberates whether to intervene more permanently, a move that underscores the high‑stakes nature of the case on the nation’s shadow docket.

The extension also highlights an unusual silence from the Food and Drug Administration, which has not filed a brief supporting the federal position. Traditionally, the government argues that lower‑court blocks of federal action cause irreparable harm, a key factor in granting extraordinary relief. Without that advocacy, the justices must weigh the equities largely on the merits of the parties’ arguments. Louisiana’s standing claim, based on alleged injuries from the telemedicine rule, faces steep scrutiny, especially as the Fifth Circuit’s ruling now conflicts with a Ninth Circuit decision that permits the same practice.

Regardless of the Court’s ultimate decision—whether it grants certiorari, issues a final stay, or lets the Fifth Circuit order stand—the immediate effect is the preservation of telehealth access to medication abortion for millions of women. The episode also fuels ongoing debate over the Supreme Court’s use of the shadow docket and the proper role of state standing in federal regulatory challenges. Legal analysts predict that a definitive ruling could set a national precedent on how the FDA’s drug‑approval authority is contested in the courts, shaping reproductive‑health policy for years to come.